Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2023-09-05

Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of Bermekimab in Patients With Moderate to Severe Atopic Dermatitis [Phase 2]

View source ↗

Summary

This Phase 2 study evaluated the safety and efficacy of bermekimab in patients with moderate to severe atopic dermatitis; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • bermekimab (bermekimab)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Atopic Dermatitis, Eczema | Phase 2 | Status: COMPLETED | Results posted: 2023-09-05